Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS:
Lightwave Logic Designing Cost Effective High-Speed Silicon Photonics Solutions Enabled By Its P(2)IC™ (Polymer Photonics Integrated Circuit) Platform
High-Density Photonic Circuitry On Silicon, Enabled By Thin Film Polymer Coatings Increases Data Rates and Reduces Cost
LONGMONT, Colo., July 12, 2016 /PRNewswire/ -- Lightwave Logic, Inc. (OTCQB: LWLG), a technology company focused on the development of Next Generation Photonic Devices and Non-Linear Optical Polymer Materials Systems for applications in high-speed fiber-optic data communications and optical computing, announced today that it has broadened its photonic device development to include its new P2IC™ (Polymer Photonics Integrated Circuit) design platform.
The P2IC™ design platform utilizes high-speed ridge waveguide and slot waveguide modulator designs that scale up in performance as well as down in cost structure. Furthermore, the new Lightwave Logic P2IC™ design platform combines the best of Polymer Photonics with the best of Silicon Photonics (SiP) to create a powerful, yet scalable platform that addresses the desires of both the telecom and datacom industries.
Going beyond exascale (1018 = quintillion calculations per second) to zettascale (1021 = sextillion calculations per second) data rates using Lightwave Logic's P2IC™ technology will drive new performance metrics in transmission speeds by sending photonic signals at data rates of 200 Gbps and beyond at costs levels much lower than industry can deliver today. In the future, P2ICs™ will allow the miniaturization of high-performance photonics components that will be needed to achieve industry leading zettascale computations needed by large computing processing and graphics systems.
Lightwave Logic's slot waveguides are being designed onto silicon platforms. With the addition of other waveguide-based Silicon Photonic (SiP) devices such as multiplexers and demultiplexers, the combined Polymer Photonics platform using SiP becomes a powerful technological solution to challenge multi-billion dollar markets for a cost-effective and scalable alternative to inorganic crystalline-based photonic devices.
While the photonics industry has applied the term Silicon Photonics to the integration of silicon-based photonics components with CMOS electronics, Silicon Photonics on its own is limited in versatility and scalability. The addition of Polymer Photonics components to a silicon platform enables P2IC™ to achieve the demands (both in performance and low cost) of a fast-growing datacom and telecom industry. P2IC™ is expected to be highly competitive with both lithium niobate as well as indium phosphide and silicon as it enters the marketplace.
The concept of integrated photonics has been the subject of first-generation device deployments and much recent discussion in the photonics industry. The term relates to the powerful and ongoing trend to miniaturize and integrate multiple photonics functions on a single silicon or indium phosphide chip and is commonly referred to as a photonics integrated circuit (PIC). P2IC™ is a PIC platform designed to include the advantages of Polymer Photonics on a Silicon Photonics platform.
Tom Zelibor, Chairman and CEO of Lightwave Logic stated, "Over the last two years we have been extending the capabilities of our P2IC™ design platform. We began with groundbreaking discoveries in polymer synthesis that are currently being implemented in our new device designs. We intend to boost performance and drive down cost similar to what was seen in the computer integrated circuit business over the last 60 years.
"During the next several months we will unveil our first ridge waveguide modulator to address the requirements of the OC-48 (2.5 Gbps) and OC-192 (10 Gbps) carrier market. Given the amount of industry interest we have previously received, this initial effort is designed to prove that our P2IC™ platform can meet commercial requirements. However, the ultimate goal remains to demonstrate that our technology is scalable to 200 Gbps and beyond. We expect to meet that demand."
What's the next news-worthy event expected?
TIA!
Ah too bad, thanks
How long has Zorik Spektor been an independent board member, any idea? Just noticed the form 3 and form 4 filed today and wasn't sure if this was a new addition...
TIA!
Do we have any inclination as to when they intend to start the Phase 2 Kevetrin trial for Ovarian Cancer?
We should be able to tell how much cash on hand we have within the next 45 days as the next 10-Q becomes due.
Looking forward to the update Leo plans on providing "shortly" per his email on 6/10. Maybe that will be enough to ease this downward pressure, hopefully followed by a partnership before end of summer.
Thanks! Hopefully there will be some new information in there. Would love to know what their current cash position is but not sure that would be the right forum to disclose.
When/where is the next investor conference Cellceutix is presenting at? I seem to remember that this was discussed recently.
TIA
Essential aspects of the regulation of the anti-tumor protein p53
6/6/2016
http://medicalxpress.com/news/2016-06-essential-aspects-anti-tumor-protein-p53.html
The RNA Molecular Biology Laboratory headed by Professor Denis Lafontaine at the Université libre de Bruxelles has just published a study in Nature Communications revealing essential aspects of the regulation of the anti-tumor protein p53.
Because p53 protects us by killing cancer cells, it is considered a "good" protein. In normal cells, which of course don't need to be killed, p53 is scarce, because it is degraded all the time. Its stabilization in cancer cells leads to cell death. The level of p53 is regulated in many different ways. Some important up-regulators of p53 are to be found in the ribosome, an essential cell nanomachine responsible for the synthesis of all the proteins in all living cells. Certain ribosomal proteins can capture and sequester a p53-degrading protein, thus preventing p53 degradation. At the heart of our cells lies an important factory called the nucleolus. This is where ribosomes are synthesized. For decades, the aspect of the nucleolus has been acknowledged as a good indicator of the health status of a cell. The shape, size, and number of nucleoli can vary greatly when a cell is stressed or diseased. Nucleolar abnormalities notably appear in cancer cells and virus-infected ones. Currently, cancer pathologists are not exploiting the full potential of the nucleolus as a biomarker, for lack of reliable quantitative tools that are robust enough for implementation in routine clinical protocols.
Professor Denis Lafontaine says "Our aim was twofold. On the one hand, we wanted to answer a fundamental biological question: what are the principles governing nucleolar integrity? We notably wondered which cell components are important in maintaining nucleolar architecture." Although the nucleolus was discovered by the Italian scientist Fontana in 1774, these basic questions have not yet been answered. To address them, the Lafontaine Lab built a high-throughput screening platform: a robot microscope that can look into thousands of cells in a very short time, checking the morphology of their most intimate details and reporting it to a tailor-made computer algorithm. As proof of concept, the Lafontaine Lab focused on what happens to the nucleolus in cells lacking a ribosomal protein. "It was like playing Mikado", says Denis Lafontaine, "We removed each ribosomal protein, one at a time, and asked our robot and software: is the nucleolar structure impacted or not?"
Professor Lafontaine carries on: "On the other hand, we wanted to develop a powerful computer code to distinguish normal from abnormal nucleoli both qualitatively and quantitatively. In other words, we wanted to be able to tell unequivocally what a nucleolus looks like in a healthy or a diseased cell. Why? Because we aimed to provide clinicians with the tool they lack."
In collaboration with Professor Christophe De Vleeschouwer of the Université catholique de Louvain (ICTEAM-ELEN), the Lafontaine Lab developed an innovative index, coined the "index of nucleolar disruption", in short the "iNo score". This score provides statistically validated information about whether the nucleolar structure is damaged or not, and if it is damaged, how severe the damage is.
Lafontaine concludes "A major conclusion of our work is that only a few among the eighty ribosomal proteins are required to maintain nucleolar structure. And the really astounding result is that the ribosomal proteins most essential to the structure of the nucleolus are precisely those which are important in regulating the p53 level. This was totally unexpected, and far more than we had hoped for. Basic research will always keep surprising us."
This work has important biomedical research applications, as the iNo score has great potential for use in clinical biology.
Explore further: Scientists discover nucleoli damage could kill cancer cells
More information: Emilien Nicolas et al, Involvement of human ribosomal proteins in nucleolar structure and p53-dependent nucleolar stress, Nature Communications (2016). DOI: 10.1038/ncomms11390
Does everyone think the plan to sell or license Prurisol is still moving forward based on the results? I assume since they were better than Anacor Pharma's P2b results we will still be able to get a premium...Any reason why we wouldn't?
Someone asked me the other day if Kevetrin could be used as a continuous maintenance therapy for folks who have had partial or complete remission of certain cancers... Has Leo or Dr Menon mentioned anything like this?
Ah I see, thanks. Unbelievable the impact those pieces have...You're right though, based on the phase 2 results now should be a good time to buy before the Phase 3 results are released in June.
Why the recent drop? Something in the 10-Q? I see plenty of cash on hand, Phase 3 STS trial results to be announced in June, lawsuits settled (from what I can tell)...Not really sure what's going on here.
Ah, ok thanks for the heads up. Will temper expectations there in the meantime. Much to look forward to this year..
Anyone have an idea of when we'll get a decision on the Rosen suit?
Even though he leaves tomorrow I'm sure he still has a substantial amount of shares he's taking with him. Not like he will miss out terribly on any potential monetary gains from options left on the table.
Assuming Aruda has a dollar amount that they are looking to hit before they stop dumping, I'd rather Aruda dump more shares now while the price is ~$1.20 since they will run out of them faster while trying to reach their goal and in turn lose their influence on the share price at a faster clip.
When will they need to file their share count again? Would be nice to see what their current count is.
Good find, thanks. Maybe we are finally getting on some radars?
Are there any timeframes mentioned in the presentations for when they expect to complete the 10 patient study with DaVita? This study is taking an absurd amount of time.
Makes me wonder if DaVita is stalling so the patent runs out before they gain much market share and so DaVita are best positioned for manufacturing their own "generic" hemopurificr ASAP.
When is the meeting in Belgium?
TIA
When will we know the judge's response to the amended complaint? Or do we already know what the next steps and time frames are with respect to that process?
TIA!
Anyone check the 10-Q recently? How are they looking on cash? TIA
Interesting timeline at the end of the presentation...
University of Bologna - Should we be expecting this Phase 2 Kevetrin trial to start soon now that the Italian summer slow-down has been over for some time?
Has recruitment for their clinical study completed yet? Any recent updates on that front?
Will be interesting to see how the company responds to these "allegations". This is just getting absurd
Could they possibly need the money for the recent lawsuit settlement?
Long term its not an issue but I assume they are selling into each positive PR which gets tiring. About 1 million shares traded (way above average) and we're up 10%, not a bad day but still curious if there was a way to track how much they had left...
Anyone know how many shares Aruda has left?
They at least had testing results from clinical trials to base the acquisition on...
We're still waiting on our results
Not sure why but the PR isn't showing up in TD Ameritrade
EDIT: Nevermind, I am seeing it there now
I'll be selling around 10K shares over Monday and Tuesday this week. If anyone is considering buying more shares and wants to coordinate let me know.
Ah, I see. Thanks for the heads up!
Apologies if this has already been answered, but how long does the SP need to be over $3 for uplisting?
TIA!
When will they need to raise money again?
Glad to hear it, thank you Snez
Thanks Steve. Any idea if those hours are continuous? Or do they stop when they go home at the end of the day and then resume the next morning?
If continuous, that amounts to ~54.2 days until the test is completed (mid-late July).
What is our next near term goal, now that we've moved past the ASM?
Is it the "Bleaching" test results? A RWM?
I imagine it was supposed to say December 2015 based on their estimated primary completion date. Maybe I'm wrong but I wouldn't think they'd hit their Primary Completion date before their Study was completed:
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: June 2016